Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 10/20 | 0.36 |
| ▸ | VHL | P40337 | 1/20 | 0.33 |
| ▸ | ELOC | Q15369 | 1/20 | 0.33 |
| ▸ | ELOB | Q15370 | 1/20 | 0.33 |
| ▸ | PPM1D | O15297 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3954202 | 0.81 | PPM1D (0.34) | VHLELOCELOBPPM1D | |
| SCHEMBL4336342 | 0.81 | PPM1D (0.34) | VHLELOCELOBPPM1D | |
| SCHEMBL4416435 | 0.81 | PPM1D (0.33) | VHLELOCELOBPPM1D | |
| SCHEMBL3477748 | 0.79 | ATM (0.36) | VHLELOCELOBPPM1D | |
| SCHEMBL4330399 | 0.79 | ATM (0.36) | VHLELOCELOBPPM1D | |
| SCHEMBL15203438 | 0.79 | ATM (0.36) | VHLELOCELOBPPM1D | |
| SCHEMBL30345061 | 0.79 | ATM (0.36) | VHLELOCELOBPPM1D | |
| SCHEMBL3528010 | 0.79 | ATM (0.36) | VHLELOCELOBPPM1D | |
| SCHEMBL30729549 | 0.79 | ATM (0.36) | VHLELOCELOBPPM1D | |
| SCHEMBL4725652 | 0.79 | BDKRB2 (0.34) | VHLELOCELOBPPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935263-B1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-12-05 | — | — | EP | disclosed |
| US-8962611-B2 | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140357618-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-12-04 | — | — | US | disclosed |
| US-8846657-B2 | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140179680-A1 | Substituted Imidazopyridines as HDM2 Inhibitors | MERCK SHARP & DOHME LLC | 2014-06-26 | — | — | US | disclosed |
| US-7875633-B2 | 4-[(4-Chlorobenzyl)oxy]-1-(4-[(1E)-3-(methylamino)-1-propen-1-yl]phenyl)pyridin-2(1H)-one; remedy for metabolic disorders such as obesity, diabetes, hormone disorder; cardiovascular disorders (stenocardia, acute or congestive heart failure); nervous system disorders (bulimia, anxiety, epilepsy etc.) | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| EP-1921065-B1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090137587-A1 | Phenylpyridone Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1921065-A1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179680-A1 | Substituted Imidazopyridines as HDM2 Inhibitors | DDX21, ING2, MDM2 | PIK3CD 2786/4885VHL 39/4885ELOC 1474/4885 |
| US-20090137587-A1 | Phenylpyridone Derivative | NAT1, NPR1, PC | PIK3CD 4287/4885VHL 1029/4885ELOC 2606/4885 |
| US-20140357618-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | DDX21, ING2, MDM2 | PIK3CD 2786/4885VHL 39/4885ELOC 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.